Ioxaglic Acid

Summary

Ioxaglic Acid (CHEMBL1201291) is an approved small-molecule radioopaque medium (ATC V08AB03).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AB03
• Clinical trials: 1
• Chemistry: 1268.9 Da · C24H21I6N5O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201291
Name	Ioxaglic Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3742
ChEBI	CHEBI:31718
ATC	V08AB03
Molecular formula	C24H21I6N5O8
Molecular weight	1268.9
InChIKey	TYYBFXNZMFNZJT-UHFFFAOYSA-N

SMILES: CC(=O)N(C)C1=C(C(=C(C(=C1I)C(=O)NCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)C(=O)NCCO)I)I)C(=O)NC)I

IUPAC name: 3-[[2-[[3-[acetyl(methyl)amino]-2,4,6-triiodo-5-(methylcarbamoyl)benzoyl]amino]acetyl]amino]-5-(2-hydroxyethylcarbamoyl)-2,4,6-triiodobenzoic acid

ChEBI definition: A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an acetyl(methyl)amino group at the 5-position.

Pharmacological roles (ChEBI): radioopaque medium.

Also known as: Acide ioxaglique, Acido ioxaglico, Hexabrix 320, Ioxaglate, Ioxaglic acid, P-286, SID56463674, SID11112801, IOXAGLIC ACID, ACIDE_IOXAGLIQUE, SID144204215, IOXAGLIC-ACID

Parent form; salt/anhydrous children: CHEMBL1200508, CHEMBL1200743

Patent coverage: 1,237 distinct patent families (3,888 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 2,835 (73%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Beta-lactamase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P00811	6.2	Potency	631	nM	CHEMBL_ACT_4636904

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01848899	PHASE4	COMPLETED	Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).